Rockefeller University Press

Table II.

Maintenance of translocon component interactions during the translocation cycle

Donor	Acceptor	Untreated	Puromycin	Pactamycin
SRα	Sec61α	34.1 ± 5.2	31.6 ± 7.3	32.2 ± 4.2
SRα	Sec61β	16.0 ± 2.2	17.2 ± 3.3	18.8 ± 2.8^{^a}
TRAPα	Sec61α	18.4 ± 6.4	13.6 ± 5.6^{^a}	15.2 ± 4.9
TRAPα	Sec61β	13.6 ± 3.5	11.1 ± 3.1^{^a}	11.8 ± 2.7
TRAM	Sec61α	17.6 ± 4.2	19.8 ± 2.9^{^a}	19.7 ± 4.4
TRAM	Sec61β	12.8 ± 2.7	11.9 ± 2.0	10.4 ± 1.1^{^a}

Donor	Acceptor	Untreated	Puromycin	Pactamycin
SRα	Sec61α	34.1 ± 5.2	31.6 ± 7.3	32.2 ± 4.2
SRα	Sec61β	16.0 ± 2.2	17.2 ± 3.3	18.8 ± 2.8^{^a}
TRAPα	Sec61α	18.4 ± 6.4	13.6 ± 5.6^{^a}	15.2 ± 4.9
TRAPα	Sec61β	13.6 ± 3.5	11.1 ± 3.1^{^a}	11.8 ± 2.7
TRAM	Sec61α	17.6 ± 4.2	19.8 ± 2.9^{^a}	19.7 ± 4.4
TRAM	Sec61β	12.8 ± 2.7	11.9 ± 2.0	10.4 ± 1.1^{^a}

Treatment is significant (P ≤ 0.01) compared with untreated cells using t test.

FRET efficiencies for the indicated donor–acceptor antibody pairs were measured and tabulated as in Table I.